CD133 (cluster of differentiation 133 or human prominin-1), a marker that was first identified on the cell surface of CD34+ hematopoietic stem cells [143], has also been used to isolate populations of CSCs from glioblastoma, prostate, pancreas, ovarian, colon, lung and liver cancer (Table 1). This evidence concerns the gene PROM1 and glioblastoma.